SCHEMBL2014820

SCHEMBL2014820

CON(C)C(=O)c1cc(Cl)c2cccnc2c1-c1cccc(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.44
PIK3CD O00329 1/20 0.42
ADAMTS5 Q9UNA0 4/20 0.40
KDM4E B2RXH2 4/20 0.40
GAA P10253 1/20 0.39
MAP4K4 O95819 1/20 0.38
HIF1A Q16665 1/20 0.38
SLC40A1 Q9NP59 1/20 0.38
DHODH Q02127 1/20 0.37
GRIN2B Q13224 1/20 0.37
CYP3A4 P08684 2/20 0.37
ALOX12 P18054 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MEN1 O00255 1/20 0.36
ALOX15B O15296 1/20 0.36
NR1I2 O75469 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2012478 0.85 TRPM8 (0.42) TRPM8KDM4EMAP4K4DHODHTACR1
SCHEMBL2015003 0.84 PIK3CD (0.46) PIK3CDADAMTS5KDM4EHIF1ACYP3A4
SCHEMBL2013802 0.82 KDM4E (0.40) ADAMTS5KDM4EGAAHIF1ASLC40A1
SCHEMBL2014967 0.79 KMT2A (0.54) KDM4EGAAHIF1ACYP3A4ALOX12
SCHEMBL2015013 0.75 HIF1A (0.44) KDM4EGAAHIF1ASLC40A1CYP3A4
SCHEMBL2017011 0.73 TRPM8 (0.41) TRPM8KDM4EDHODHALDH1A1LMNA
SCHEMBL12122868 0.73 TRPM8 (0.44) TRPM8MAP4K4GRIN2B
SCHEMBL2012014 0.72 KDM4E (0.48) PIK3CDKDM4EMAP4K4SLC40A1DHODH
SCHEMBL2015215 0.72 L3MBTL1 (0.44) TRPM8PIK3CDKDM4EMAP4K4ALOX12
SCHEMBL1325440 0.72 TRPM8 (0.45) TRPM8GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680108-B2 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors INCYTE CORPORATION (US) 2014-03-25 US disclosed
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION 2011-07-28 US disclosed
WO-2011075630-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183985-A1 SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS PIK3R1, PIK3R3, PIK3R2 TRPM8 4741/4885PIK3CD 13/4885ADAMTS5 4400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.